🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to announce Pediatric Kidney Cancer Focus Awards – $75,000 in partnership with Kidney Cancer. Required Focus: Pediatric kidney cancer, specifically translocation RCC Apply at joeywings.org/grant/

👇The Clinical Cancer Research cover below is a #RenalMedullaryCarcinoma cell expressing MUC16 (CA-125) in green and actin red with overlapping regions in yellow. Photo taken by Menuka Karki #MsaouelLab and also featured in our art contest led by Eleonora Dondossola,PhD Full article: aacrjournals.org/clincancerres/…

KCA funding helped Srinivas Viswanathan #tRCC research at a critical moment in his career. Children with this rare #kidneycancer will benefit from his discoveries and he is on a path to continue making progress for the field! Apply now for a KCA Research Award: kidneycancer.org/grants/

Our latest study in EMBO Mol. Medicine reveals how TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma (tRCC). We define tRCC as a novel metabolic subtype of renal cancer. IGBMC - Srinivas Viswanathan 🔗embopress.org/doi/full/10.10…

Love this!

1/ Excited to share our new paper in npj Digital Medicine. We worked with Fei Wang to develop a cutting-edge AI model 🖥️ that predicts response to neoadjuvant chemotherapy 💉 in patients with muscle-invasive #bladdercancer in the S1314 randomized clinical trial

Save the date: FORTRESS 2026 in Leuven Belgium)! Follow further announcements via kuleuven.be/fortress

🎉Thrilled to support AACR Scholars-in-Training Dr. Xiaofan Lu & Dr. Emily Arner, with Chris Johnson Foundation Inc.. Thanks to all the fellow #kidneycancer supporting orgs and congrats to all the 2025 awardees! #aacr25 #cancerresearchsaveslives

Congratulations Payal Kapur B.C. Leibovich MD Mayo Clinic Genentech KidneyCancerProgram UTSW Simmons Cancer Center UTSWPATH on identification of #RCC determinants of late mets academic.oup.com/jnci/article-a…

Happy to share the team latest investigation of BIONIK trial showing unexpectedly that angiogenic signature is associated with response to immunotherapy in ccRCC, against the current dogma! @igbmc thanks to Stéphane Oudard nature.com/articles/s4169…

1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest Immunity study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/article/S10… #MsaouelLab

Congratulations to our one of a kind #AI #kidneycancer KidneyCancerProgram UTSW Computational Biology team with David Hein, Alana Christie, Bing Xie,Joseph Vento, MD, MS Andrew Jamieson Payal Kapur on npj Digital Medicine #LLM paper rdcu.be/enlxw

📢The KCA & UT Southwestern Medical Center invite researchers to participate in the *FIRST* RCC Animal Model Workshop this Sept 11-13! ‼️Apply by June 30, space limited‼️ Join us to drive research and accelerate therapeutics from lab to clinic. Email Salvatore La Rosa: [email protected]

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

‼️🚨Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer a new SOC ⁦NEJM⁩ nejm.org/doi/full/10.10…

Amazing article by Siddhartha Mukherjee on the promises and perils of cancer early detection. Really resonated with me as I touched on several of the themes discussed here in my talk at the G7 conference on poor prognosis cancers. newyorker.com/magazine/2025/…

1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out Journal of Clinical Oncology !!! Incredibly thankful to my mentors David Braun Toni Choueiri, MD Eli Van Allen and all co-authors Dana-Farber BIDMC IM Residency Yale University Brigham and Women's Hospital Link: ascopubs.org/doi/10.1200/JC…

🚨 New Meta-Analysis in Metastatic non–Clear Cell RCC (nccRCC) Key pooled outcomes (23 studies): 🎯 ORR: 26.6% 🛡️ DCR: 57.8% ⏳ Median PFS: 6.6 months 📈 Median OS: 21.1 months Takeaway: ICI-based therapies, especially when combined with targeted agents, show superior efficacy

🚨A fantastic review for non-clear cell renal cell carcinoma! in Nature Reviews Urology 👉Time to tailor, not generalize: 🔬 Genotype-driven subtyping (e.g. MET, FH, TSC-mTOR, ALK, MITF, SMARCB1) enables precision therapy. 💊 Cabozantinib & savolitinib show promise in MET-driven tumors.

1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospective study Urologic Oncology asks: does VIGOROUS exercise raise risk? 👉pubmed.ncbi.nlm.nih.gov/40617795/ #MsaouelLab